Punekar, Salman R.
Velcheti, Vamsidhar
Neel, Benjamin G.
Wong, Kwok-Kin http://orcid.org/0000-0001-6323-235X
Article History
Accepted: 20 July 2022
First Online: 26 August 2022
Competing interests
: V.V. has received fees for consulting or serving on advisory boards from Amgen, AstraZeneca, Bristol Myers Squibb (BMS), EMD Serono, Foundation Medicine, GlaxoSmithKline, Iteos Therapeutics, Merck, Novartis and Novocure. B.G.N. is a co-founder, holds equity in and receives consulting fees from Lighthorse Therapeutics and Navire Pharmaceuticals; is a co-founder and holds equity in Northern Biologics; is a scientific advisory board (SAB) member for, holds equity in and receives consulting fees from Arvinas; and is an SAB member for and holds equity in Recursion Pharma. K.-K.W. is a co-founder of and holds equity in G1 Therapeutics; has received grants from Alkermes, Ansun, AstraZeneca, BMS, Dracen, Merus, Mirati, Takeda and Tvardi; grants and personal fees from Delfi, Janssen, Pfizer and Zentalis; personal fees from Navire, Prelude and Recursion; and grants from Ono outside the submitted work. S.R.P. declares no competing interests.
Free to read: This content has been made available to all.